Overview

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if sequential administration of decitabine and clofarabine can help to control MDS better than decitabine alone. The safety of this drug combination will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Azacitidine
Clofarabine
Decitabine